Study of XB010 in Subjects With Solid Tumors

Launched by EXELIXIS · Aug 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called XB010 for patients with locally advanced or metastatic solid tumors, which are cancers that have spread and cannot be removed through surgery. The main goals of the study are to find out if XB010 is safe, how well the body tolerates it, and if it shows any early signs of being effective against these cancers. Participants will also receive a drug called pembrolizumab in some cases. This trial is particularly important for patients who do not have other treatment options available or whose current treatments are no longer working.

To be eligible for the trial, patients must be at least 18 years old and have a confirmed diagnosis of a specific type of solid tumor that cannot be operated on. They should be in good health overall, as indicated by specific performance status scores, and must have adequate organ function. The study is currently recruiting participants of all genders, and those who join can expect careful monitoring throughout the trial. Importantly, participants will need to provide a sample of their archived tumor tissue for analysis. This research could help develop new treatment options for patients facing tough cancer challenges.

Gender

ALL

Eligibility criteria

• • Age 18 years or older on the day of consent.
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
• • Adequate organ and marrow function.
• • Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
• • The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer).
• • Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.